| (B) |   1. | 
¤@¦ì46·³¤k©Ê¯f¤H¡A¦]µo¿N¡B¬È´H¡B¥k°¼¸y³¡¯kµh¦Ó¨Ó«æ¶E¡A°Ý¶E¥çµo²{ªñ¤é¦³ÀW§¿²{¶H¡A¸g§¿²GÀˬdµo²{¦³WBC>100/ HPF¡A§¿²G°ö¾i¤Î¦å²G°ö¾i§¡ªø¥XEnterococcus faecalis¡A¹ï©Ò´ú¸Õ¤§§Ü¥Í¯À§¡¨ã±Ó·P©Ê¡]susceptible¡^¡A½Ð°Ý¤U¦C¦óºØÃĪ«ªvÀø¤è¦¡¬O³Ì¦X¾A¤§¿ï¾Ü¡H
 | 
| A. | Cefazolin+gentamicin | 
| B. | Ampicillin+gentamicin | 
| C. | Trimethoprim¡þsulfamethoxazole | 
| D. | Ceftriaxone alone | 
| E. | Cefazolin alone | 
|   | 
| (A) |   2. | 
µû¦ôÃþ·Àã©ÊÃö¸`ª¢¤§¯e¯f¬¡©Ê(disease activities),¤U¦C¨º¤@¶µ³Ì¤£¨ã¬¡©Ê«ü¼Ð?
 | 
| A. | Ãþ·Àã¦]¤l¿@«×  | 
| B. | ¸~µÈÃö¸`¤§¼Æ¥Ø | 
| C. | ESR¤W¤Éµ{«× | 
| D. | ¯f¤H¦Û¨¤§ÄY««×µû¦ô(patient's global assessment)  | 
| E. | À£µhÃö¸`¤§¼Æ¥Ø  | 
|   | 
| (B) |   3. | 
¤U¦C¦³Ãö«ÕªùÁ³±Û±ìµß(Helicobacter pylori)ªº±Ôz¡A¦óªÌ¥¿½T? 1.80%·P¬VªÌ·|¦³®ø¤Æ©Ê¼ìºÅ¡A2.°£µß«á¬ù60-75%ªºGÂH½¤¬ÛÃö²O¤Ú²Õ´²O¤ÚÀù(mucosa-associated lymphoid tissue lymploma)¥i¥H±o¨ì½w¸Ñ¡A3.»PG¶NªùÀùµo¥Í¦³Ãö¡A4.ÄÝ©ó¨ã¦³§¿¯ÀúC(urease)¤§²Äõ¤ó³±©Êµß(Gram-negative bacteria)
 | 
| A. | 1+3 
 | 
| B. | 2+4 | 
| C. | 1+4  | 
| D. | 3+4  | 
| E. | 1+2  | 
|   | 
| (B) |   4. | 
¦bÀR¯ß¦åºÞ¤º®ê¶ë¯fÅܤ¤¡A©Ò¿×Virchow's triad¥]¬A¦³¡G
 | 
| A. | hypercoagulability, thrombocytosis¤Îvenous stasis  | 
| B. | hypercoagulability, venous stasis¤Îvascular injury  | 
| C. | hypercoagulability, venous obstruction¤Îendothelial dysfunction  | 
| D. | thrombocytosis, venous obstruction¤Îatrio-venous fistula  | 
| E. | thrombocytosis, venous stasis¤Îvascular injury  | 
|   | 
| (A) |   5. | 
¤U¦C¦óºØ¯f¤H¤£¾A¦X±µºØ¬y·P¬Ì](influenza vaccine)¡H
 | 
| A. | ¹ï³JÃþ»s«~¹L±Ó | 
| B. | µÇ°IºÜ  | 
| C. | ¨xµw¤Æ | 
| D. | ¿}§¿¯f  | 
| E. | ÷¨Å¤§°ü¤k  | 
|   | 
| (A) |   6. | 
45·³¨k©Ê¥D¶D¤W¸¡µh¡A¨ÅéÀˬdµo²{¦³»´«×µo¿N¡A¦åÀ£¥¿±`¡A¤W¸¡¦³À£µh¥~¡A¨ä¾lÀˬd¨ÃµL¯S®í¡A¸¡³¡¹q¸£Â_¼hÀˬdµo²{¥ªµÇ¤W¸¢¦³ 1 Ó 3 x 3 ¤½¤À¸~½F¡A½Ð°Ý±z¦p¦ó³B¸m ?
 | 
| A. | Àˬd 24 hr urine cortisol ©Mcatecholamine  | 
| B. | ¶i¦æ¹q¸£Â_¼h¾É¤Þ²Ó°w¬ï¨ë²ÓM¾ÇÀˬd  | 
| C. | ¦w±ÆºÏ®¶Äá¼vÀˬd  | 
| D. | Âश¥~¬ì¶}¤M¤Á°£ | 
| E. | ¦w±Æ 6 Ó¤ë«á¹q¸£Â_¼hÀˬd°lÂÜ  | 
|   | 
| (C) |   7. | 
60·³¤k©Ê¬ù15¦~«e¶EÂ_¦³²Ä2«¬¿}§¿¯f¡A¦¹«á¶}©lªA¥Î¤fªA°¦å¿}ÃĪ«¡A¥Ø«eªA¥ÎGlimepiride 6 mg qd¡A pioglitazone 30 mg qd¡A metformin 850 mg tid¡C ¥D¶Dªñ3Ó¤ë¨Ó¦å¿}±±¨î¤£¨}¥BÅé«´î¤Ö3¤½¤ç¡A¯f¤H§_»{¶¼¹¡B¹B°Ê²ßºD²§©ó©¹±`¡C¨ÅéÀˬd¡G¦åÀ£135/85 mmHg ¡B PR 96/min ¡B regular¡A BMI 27¡A ¦¹¥~µL¯S®í¡C©â¦åÀˬdAC 220 mg/dL¡A PC 250 mg/dL ¡AHbA1C 9.0%¡ACholesterol 200 mg/dL ¡ALDL-C 100 mg/dL¡A HDL-C 35 mg/dL ¡ATG 300 mg/dL¡A BUN 35 mg/dL¡A Creatinine 1.2 mg/dL ¡ANa 135 mM¡A K 3.8 mM¡A Urinalysis
¡Gprotein++¡F¸g¦^ÅU¯f¤H¶¼¹¤Î¹B°Ê¶q©|¥i¡C¤U¦C³B¸m¦óªÌ¾A©y¡G(1)¼W¥[¤fªA°¦å¿}ÃĪ«¾¯¶q¤ÎºØÃþ¡A(2)µ¹¤©´îªÎÃĨÏBMI°¦Ü23¡A(3)µ¹¤©ACEI(Angiotensin- Converting Enzyme Inhibitor)¡A(4)§ï¥Î¯Ø®q¯ÀªvÀø¡A(5)µ¹¤©statinªvÀø¨ÏLDL-C°¦Ü70 mg/dL
 | 
| A. | 1+2 | 
| B. | 2+3 | 
| C. | 3+4 | 
| D. | 4+5  | 
| E. | 5+1  | 
|   | 
| (D) |   8. | 
¤@¦ì41·³¤k©Ê¡A±w¦³ºC©ÊB«¬¨xª¢¨Ö¨xµw¤Æ¡A¦b¨Ò¦æÀˬd¤¤µo²{¦å²G¬Û¦p¤U¡G¦å¬õ¯À13.5 g/dL¡A¥Õ¦å²y4,150/£gL¤ÀÃþ¥¿±`¡A¦å¤pªO67,000/£gL¡C²£¥Í³oºØÅܤƳ̱`¨£ªºì¦]¬°¦ó¡H
 | 
| A. | Idiopathic thrombocytopenic purpura  | 
| B. | Thrombotic thrombocytopenic purpura | 
| C. | Systemic lupus erythematosus  | 
| D. | Hypersplenism  | 
| E. | Human immunodeficiency virus infection  | 
|   | 
| (E) |   9. | 
¦³¤@¦ì45·³¨k©Ê¯f¤H¡A¦]µo¿N¤Î¤UªÏ³n²Õ´·P¬V¦Ó¦Ü«æ¶E³B´N¶E¡A·P¬V¯f¨_¤§Áw²G°ö¾iªø¥Xmethicillin-resistant Staphylococcus aureus¡]MRSA¡^¡A¤U¦C¦óºØÃĪ«¤£¾A¦X¥Î©óªvÀø¦¹¯f¤H¡H
 | 
| A. | Vancomycin | 
| B. | Teicoplanin | 
| C. | Linezolid | 
| D. | Daptomycin | 
| E. | Imipenem | 
|   | 
| (D) |  10. | 
¤@22·³¨k©Ê¯f±w©ó³Ìªñ¨âӤ뤺¦b¥kÀV³¡ªø¥X¤@13¤½¤À¸~½F¡A¤Á¤ùÀˬdÅã¥Ü¬°²O¤Ú½F lymphocytic lymphoma¡F¯f±w±µ¨ü¤Æ¾ÇªvÀø¡A©óªvÀø«á²Ä¤G¤Ñ¸~½F§Y©úÅãÁY¤p¡A¦ý¬OªvÀø«á²Ä¤T¤Ñ¯f±w§¿²G´î¤Ö¡A¦å²GÀˬd¬°«æ©ÊµÇ°IºÜ¡F¦¹¯f±w³Ì¤£¥i¯à¦X¨Ö¤U¦C¦óºØ¥NÁ²§±`¡H
 | 
| A. | ¥NÁ©ʻĦå¯g (metabolic acidosis)  | 
| B. | °ª¦å¹[¯g (hyperkalemia)  | 
| C. | °ª¦åÁC¯g(hyperphosphatemia)  | 
| D. | °ª¦å¶t¯g(hypercalcemia)  | 
| E. | °ª§¿»Ä¦å¯g(hyperuricemia)  | 
|   | 
| (D) |  11. | 
¤@¦ì51·³¤k©Ê±`±`ı±o²´·ú¦³²§ª«·P¦³¤T¦~¤§¤[¡A¤]¦³»´·Lªº¤f°®¡C²z¾ÇÀˬdµo²{¨â²´¦³µ²½¤ª¢¤Î°®Àê¡C½Ð°Ý¤U¦C¦óºØÀˬd¹ï¨ä¶EÂ_³Ì¦³À°§U?
 | 
| A. | Slit lamp examination | 
| B. | Ophthalmoscopic examination  | 
| C. | Rose-Bengal staining  | 
| D. | Schirmer's test | 
| E. | Sialoscintigraph | 
|   | 
| (D) |  12. | 
¤@¦ì22·³ªº¨k©Ê¦b¶]§¹°¨©ÔªQÁɶ]«á¡A³Q°e¨ì«æ¶E³B¨Ó¡A¥Lªº¥D¶D¬O·¥«×¤f´÷»PÀY·w¡C·í®É¦åÀ£¬°90/60 mmHg¡A¤U¦C¦U¶µÀËÅç¼Æ¾Ú³£¦³¥i¯à¡A°£¤F¡G
 | 
| A. | Hematocrit °ª©ó¥¿±`È  | 
| B. | Urine specific gravity >1.018  | 
| C. | BUN/Cre ratio > 20  | 
| D. | Urine osmolarity < 300 mosmol/L  | 
| E. | Urine sodium < 20 mEq/L | 
|   |